OnKure Therapeutics, Inc. (OKUR)
Healthcare · NGM
Fundamentals
Valuation and ratings
OnKure Therapeutics, Inc. trades at USD4.12, close to the USD4.56 our discounted cash flow model puts on the business. On this measure the market and the model broadly agree, so the interesting question is which of them is wrong.
Our moat model scores it 10 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
OKUR earnings and analyst estimates
Recommendation mix, 6 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
OKUR passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is OnKure Therapeutics, Inc. (OKUR) undervalued?
Against our discounted cash flow estimate of USD4.56, OKUR at USD4.12 is 11% below fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
The full research page for OKUR, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.